A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150
This study is recruiting at 5 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Colorectal Cancer
- Pancreatic Cancer
- Non-Small Cell Lung Cancer
- Solid Tumor
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- PAQ Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- July 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Dana-Farber/Massachusetts General Hospital, Inc · Boston, MA
Texas · 2
- New Experimental Therapeutics of San Antonio LLC · San Antonio, TX
- START - South Texas Accelerated Research Therapeutics, LLC · San Antonio, TX
Utah · 1
- START Mountain Region · West Valley City, UT
Virginia · 1
- NEXT Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.